https://orcid.org/0000-0002-4463-0835
References
- Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–919.
- Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280–2289.
- Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554–557.
- Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480.
- Karube K, Feldman AL. “Double-hit” of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative. Blood. 2020;135(9):700.
- Pedersen MB, Relander T, Lauritzsen GF, et al. The impact of upfront autologous transplant on the survival of adult patients with ALCL and PTCL NOS according to their ALK, DUSP22, and TP63 gene rearrangement status—a joined Nordic lymphoma group and Mayo clinic analysis. Blood. 2017;130(Suppl_1):822–822.
- Savage KJ, Harris NL, Vose JM, et al. ALK − anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-Cell lymphoma project. Blood. 2008;111(12):5496–5504.
- King RL, Dao LN, McPhail ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol. 2016;40(1):36–43.
- Wang X, Boddicker RL, Dasari S, et al. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Hum Pathol. 2017;64:19–27.